A bipartisan group of state attorneys general is calling on federal agencies to license Gilead Sciences' remdesivir to other manufacturers to end shortages of the anti-viral drug used to treat COVID-19 patients and make it more affordable. | |
News Alert Tuesday, August 4 |
|
| | | | |
|